Preliminary evaluation of percutaneous treatment of echinococcal cysts without injection of scolicidal agent

Giovanni Firpo, Ambra Vola, Raffaella Lissandrin, Francesca Tamarozzi, Enrico Brunetti

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Puncture, Aspiration, Injection of scolicidal agent, Re-aspiration is the most widely used percutaneous treatment of cystic echinococcosis (CE). Among its perceived risks is chemical sclerosing cholangitis, a serious complication due to the caustic effect of the scolicidal solution on the biliary tree, when a patent cystobiliary fistula occurs. To simplify the protocol, we decided to omit injection and reaspiration of the scolicidal agent and to implement a full course of albendazole (ABZ) therapy instead of the routine 1-month ABZ prophylaxis. We searched our databases for patients with CL (Cystic Lesion, suspected for CE), CE1, and CE3a cysts treated between October 2007 and January 2017 with percutaneous aspiration followed by at least 1 month of oral ABZ and with an ultrasound follow-up of at least 6 months. Fifteen patients matched our inclusion criteria. Follow-up ranged from 7 to 75 months. The oral ABZ course after the aspiration procedure ranged from 1 to 18 months. Eleven subjects (73.3%) had undergone a course of ABZ before the percutaneous procedure (min 15 days, max 16 months). Ten cysts (62.5%) had reached solidification (stage CE4) in 3 to 69 months. Four other cysts (26.7%) remained stable in stage CE3a, whereas two cysts (13.3%) reactivated to stage CE3b. Procedural perioperative complications occurred in 13.3% of patients, whereas complications during the followup occurred in 20% of patients. These proof-of-concept preliminary results are overall comparable with those reported in the literature for other percutaneous treatments, both in terms of response rate, relapse rate, and morbidity.

Original languageEnglish
Pages (from-to)1818-1826
Number of pages9
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume97
Issue number6
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Albendazole
Cysts
Injections
Echinococcosis
Paracentesis
Therapeutics
Caustics
Sclerosing Cholangitis
Biliary Tract
Fistula
Databases
Morbidity
Recurrence

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases
  • Virology

Cite this

Preliminary evaluation of percutaneous treatment of echinococcal cysts without injection of scolicidal agent. / Firpo, Giovanni; Vola, Ambra; Lissandrin, Raffaella; Tamarozzi, Francesca; Brunetti, Enrico.

In: American Journal of Tropical Medicine and Hygiene, Vol. 97, No. 6, 01.01.2017, p. 1818-1826.

Research output: Contribution to journalArticle

@article{8a7fa1d822144f35a24089ef90833477,
title = "Preliminary evaluation of percutaneous treatment of echinococcal cysts without injection of scolicidal agent",
abstract = "Puncture, Aspiration, Injection of scolicidal agent, Re-aspiration is the most widely used percutaneous treatment of cystic echinococcosis (CE). Among its perceived risks is chemical sclerosing cholangitis, a serious complication due to the caustic effect of the scolicidal solution on the biliary tree, when a patent cystobiliary fistula occurs. To simplify the protocol, we decided to omit injection and reaspiration of the scolicidal agent and to implement a full course of albendazole (ABZ) therapy instead of the routine 1-month ABZ prophylaxis. We searched our databases for patients with CL (Cystic Lesion, suspected for CE), CE1, and CE3a cysts treated between October 2007 and January 2017 with percutaneous aspiration followed by at least 1 month of oral ABZ and with an ultrasound follow-up of at least 6 months. Fifteen patients matched our inclusion criteria. Follow-up ranged from 7 to 75 months. The oral ABZ course after the aspiration procedure ranged from 1 to 18 months. Eleven subjects (73.3{\%}) had undergone a course of ABZ before the percutaneous procedure (min 15 days, max 16 months). Ten cysts (62.5{\%}) had reached solidification (stage CE4) in 3 to 69 months. Four other cysts (26.7{\%}) remained stable in stage CE3a, whereas two cysts (13.3{\%}) reactivated to stage CE3b. Procedural perioperative complications occurred in 13.3{\%} of patients, whereas complications during the followup occurred in 20{\%} of patients. These proof-of-concept preliminary results are overall comparable with those reported in the literature for other percutaneous treatments, both in terms of response rate, relapse rate, and morbidity.",
author = "Giovanni Firpo and Ambra Vola and Raffaella Lissandrin and Francesca Tamarozzi and Enrico Brunetti",
year = "2017",
month = "1",
day = "1",
doi = "10.4269/ajtmh.17-0468",
language = "English",
volume = "97",
pages = "1818--1826",
journal = "American Journal of Tropical Medicine and Hygiene",
issn = "0002-9637",
publisher = "American Society of Tropical Medicine and Hygiene",
number = "6",

}

TY - JOUR

T1 - Preliminary evaluation of percutaneous treatment of echinococcal cysts without injection of scolicidal agent

AU - Firpo, Giovanni

AU - Vola, Ambra

AU - Lissandrin, Raffaella

AU - Tamarozzi, Francesca

AU - Brunetti, Enrico

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Puncture, Aspiration, Injection of scolicidal agent, Re-aspiration is the most widely used percutaneous treatment of cystic echinococcosis (CE). Among its perceived risks is chemical sclerosing cholangitis, a serious complication due to the caustic effect of the scolicidal solution on the biliary tree, when a patent cystobiliary fistula occurs. To simplify the protocol, we decided to omit injection and reaspiration of the scolicidal agent and to implement a full course of albendazole (ABZ) therapy instead of the routine 1-month ABZ prophylaxis. We searched our databases for patients with CL (Cystic Lesion, suspected for CE), CE1, and CE3a cysts treated between October 2007 and January 2017 with percutaneous aspiration followed by at least 1 month of oral ABZ and with an ultrasound follow-up of at least 6 months. Fifteen patients matched our inclusion criteria. Follow-up ranged from 7 to 75 months. The oral ABZ course after the aspiration procedure ranged from 1 to 18 months. Eleven subjects (73.3%) had undergone a course of ABZ before the percutaneous procedure (min 15 days, max 16 months). Ten cysts (62.5%) had reached solidification (stage CE4) in 3 to 69 months. Four other cysts (26.7%) remained stable in stage CE3a, whereas two cysts (13.3%) reactivated to stage CE3b. Procedural perioperative complications occurred in 13.3% of patients, whereas complications during the followup occurred in 20% of patients. These proof-of-concept preliminary results are overall comparable with those reported in the literature for other percutaneous treatments, both in terms of response rate, relapse rate, and morbidity.

AB - Puncture, Aspiration, Injection of scolicidal agent, Re-aspiration is the most widely used percutaneous treatment of cystic echinococcosis (CE). Among its perceived risks is chemical sclerosing cholangitis, a serious complication due to the caustic effect of the scolicidal solution on the biliary tree, when a patent cystobiliary fistula occurs. To simplify the protocol, we decided to omit injection and reaspiration of the scolicidal agent and to implement a full course of albendazole (ABZ) therapy instead of the routine 1-month ABZ prophylaxis. We searched our databases for patients with CL (Cystic Lesion, suspected for CE), CE1, and CE3a cysts treated between October 2007 and January 2017 with percutaneous aspiration followed by at least 1 month of oral ABZ and with an ultrasound follow-up of at least 6 months. Fifteen patients matched our inclusion criteria. Follow-up ranged from 7 to 75 months. The oral ABZ course after the aspiration procedure ranged from 1 to 18 months. Eleven subjects (73.3%) had undergone a course of ABZ before the percutaneous procedure (min 15 days, max 16 months). Ten cysts (62.5%) had reached solidification (stage CE4) in 3 to 69 months. Four other cysts (26.7%) remained stable in stage CE3a, whereas two cysts (13.3%) reactivated to stage CE3b. Procedural perioperative complications occurred in 13.3% of patients, whereas complications during the followup occurred in 20% of patients. These proof-of-concept preliminary results are overall comparable with those reported in the literature for other percutaneous treatments, both in terms of response rate, relapse rate, and morbidity.

UR - http://www.scopus.com/inward/record.url?scp=85037027608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037027608&partnerID=8YFLogxK

U2 - 10.4269/ajtmh.17-0468

DO - 10.4269/ajtmh.17-0468

M3 - Article

C2 - 29016329

AN - SCOPUS:85037027608

VL - 97

SP - 1818

EP - 1826

JO - American Journal of Tropical Medicine and Hygiene

JF - American Journal of Tropical Medicine and Hygiene

SN - 0002-9637

IS - 6

ER -